Novo Nordisk CEO Maziar Mike Doustdar discusses demand for the Danish firm’s weight-loss drug Wegovy and diabetes medication Ozempic. He also comments on the $10 billion bid for obesity startup Metsera and the prospects for a deal with the Trump administration on US pricing. He speaks to Bloomberg’s Guy Johnson in Bagsvaerd, Denmark. (Source: Bloomberg)
www.bloomberg.com
#Novo #Nordisk #CEO #Doustdar #Headwinds #Metsera #Bid #Pricing
Novo Nordisk CEO Doustdar on Headwinds, Metsera Bid, US Pricing
